M&A / Deals Sandoz targets industry patent void with $322m Henlius deal Pharmaceutical TechnologySandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.Read full story pharminent August 17, 2026 (Last updated: August 18, 2026) Pharmaceutical Technology Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities. Read full story Post navigation Previous: Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approvalNext: Novo Nordisk and AWS form AI partnership to speed drug discovery Related Stories M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026 M&A / Deals PTC takes a chance on Sangamo’s Fabry disease gene therapy pharminent August 13, 2026 M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset pharminent August 12, 2026
